Abstract:Background: Axitinib (AXI) is approved for second-line treatment of advanced RCC. This Phase 3, randomized, double-blind trial compared the efficacy and safety of adjuvant AXI vs placebo (PBO) in patients (pts) at high risk of recurrent RCC. Methods: Pts had undergone nephrectomy; >50% clear-cell RCC; no evidence of macroscopic residual or metastatic disease (independent review committee [IRC] confirmed). The intent-to-treat (ITT) population (pop) was all randomized pts ≥pT2 and/or N1 with any Fuhrman grade (FG) and ECOG PS 0-1. Pts (stratified by risk group and country) received (1:1) oral AXI 5 mg twice daily (BID) or PBO for up to 3 y, with min 1 y until recurrence, evidence of a second primary malignancy, significant toxicity, or consent withdrawal. Max dose increases to 10 mg BID and decreases to 1 mg BID were allowed. The primary endpoint was disease-free survival (DFS; IRC). Secondary endpoints were overall survival (OS) and safety. Results: 724 pts were included: 363 AXI and 361 PBO. Most pts were Asian (73.3%), median age 58.0 y and highest risk (56.5%; defined as pT3 with FG ≥ 3 or pT4 and/or N1 with any FG). The study was stopped due to futility at a preplanned interim analysis at 203 DFS (IRC) events. DFS in the ITT pop and highest and lower risk subpops are shown in the table. OS data were not mature (deaths: 7.7% AXI and 7.2% PBO). Median (range) treatment duration was 19.9 (0.1-37.0) mo for AXI and 21.9 (0.0-36.9) mo for PBO. More adverse events (AEs; 98.6% vs 92.5%), serious AEs (19.4% vs 14.5%), grade 3-4 AEs (61.2% vs 30.1%), dose reductions (56.2% vs 8.4%), interruptions (51.4% vs 21.7%) and discontinuations due to AEs (23.3% vs 11.1%) were reported for AXI vs PBO. The most common AE was hypertension: 64.3% and 24.5%, respectively.Table: 863OSummary of disease-free survivalITT popaAxitinib (N = 363)Placebo (N = 361)Based on IRCMedian (95% CI), yNR (4.1-NR)NR (4.1-NR)HR (95% CI)0.870 (0.660-1.147)P value0.3211Based on investigator assessmentMedian (95% CI), yNR (3.6-NR)NR (4.1-NR)HR (95% CI)0.776 (0.599-1.005)P value0.0536Highest risk popbAxitinib (N = 209)Placebo (N = 200)Based on IRCMedian (95% CI), yNR (3.5-NR)NR (2.5-NR)HR (95% CI)0.735 (0.525-1.028)P value0.0704Based on investigator assessmentMedian (95% CI), y4.4 (3.4-NR)2.8 (1.5-NR)HR (95% CI)0.641 (0.468-0.879)P value0.0051Lower risk popbAxitinib (N = 146)Placebo (N = 149)Based on IRCMedian (95% CI), yNR (NR-NR)NR (NR-NR)HR (95% CI)1.016 (0.620-1.666)P value0.9483Based on investigator assessmentMedian (95% CI), yNR (NR-NR)NR (NR-NR)HR (95% CI)1.048 (0.654-1.681)P value0.8445CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group Performance Score; HR, hazard ratio; IRC, independent review committee; ITT, intent-to-treat; NR, not reached aHR and its CIs are obtained from the Cox proportional hazards model stratified by risk group. Two-sided P values based on the log-rank test stratified by risk group. bHR and its CIs are obtained from an unstratified Cox proportional hazards model. Two-sided P values based on an unstratified log-rank test. ITT pop included all randomized pts ≥pT2 and/or N1 with any Fuhrman grade and ECOG PS 0-1. The highest risk pop had pT3 with Fuhrman grade ≥3 or pT4 and/or N1 with any Fuhrman grade. The lower risk pop had pT2 or pT3 with Fuhrman grade ≤2. Open table in a new tab CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group Performance Score; HR, hazard ratio; IRC, independent review committee; ITT, intent-to-treat; NR, not reached aHR and its CIs are obtained from the Cox proportional hazards model stratified by risk group. Two-sided P values based on the log-rank test stratified by risk group. bHR and its CIs are obtained from an unstratified Cox proportional hazards model. Two-sided P values based on an unstratified log-rank test. ITT pop included all randomized pts ≥pT2 and/or N1 with any Fuhrman grade and ECOG PS 0-1. The highest risk pop had pT3 with Fuhrman grade ≥3 or pT4 and/or N1 with any Fuhrman grade. The lower risk pop had pT2 or pT3 with Fuhrman grade ≤2. Conclusions: In ATLAS, there were no significant differences between AXI and PBO for DFS in the ITT pop and lower risk subpop, whereas a significant difference for DFS per investigator was seen in the highest risk subpop. No new safety signals were seen in pts at high risk of recurrent RCC. Clinical trial identification: NCT01599754. Editorial acknowledgement: Medical writing support was provided by Anne Marie McGonigal, PhD, of Engage Scientific Solutions, and funded by Pfizer. Legal entity responsible for the study: SFJ Pharma and Pfizer. Funding: SFJ Pharma and Pfizer. Disclosure: M. Gross-Goupil: BMS, Ipsen, Novartis, Pfizer, Roche. R. Debenedetto, R. Linke: Employee of SFJ Pharmaceuticals. M. Casey, B. Rosbrook, M.J. Lechuga Frean, O. Valota: Employee of Pfizer Inc. E. Grande: Advisory board services and honoraria: Pfizer, BMS, Roche, EUSA Pharma, Astra Zeneca. D.I. Quinn: Advisory board services and honoraria: Pfizer, Bayer, Novartis, BMS, Merck, Exelixis, Genentech, Roche, Janssen, Astra Zeneca, Astellas. All other authors have declared no conflicts of interest.

A pilot study of oral paclitaxel (ORAXOL) in subjects with cutaneous angiosarcomas (KX-ORAX-010)

A novel oral paclitaxel and HM10381 (oraxel)-treated metastatic breast cancer: A phase I study (KX-ORAX-CN-007).

A randomized, controlled, multi-center, open-label study of adjuvant nab-paclitaxel plus S-1 (AS) versus capecitabine plus oxaliplatin (CapeOX) for stage III gastric cancer after D2 resection.

[OPTIMAL 3] A Phase III Trial to Evaluate the Efficacy and Safety of DHP107 (liporaxel, Oral Paclitaxel) Compared to Taxol (IV Paclitaxel) As First Line Therapy in Patients with Recurrent or Metastatic HER2 Negative Breast Cancer (BC) (NCT03315364).

A Phase I Study of TAK-659 and Paclitaxel in Patients with Taxane-Refractory Advanced Solid Tumors.

A Phase Ii, Open-Label, Multicenter, Prospective Study of Paclitaxel Plus Capecitabine with Subsequent Capecitabine Maintenance Therapy As First-Line Treatment for Metastatic or Recurrent Gastric Cancer

Open-label Randomized Study of Individualized Pharmacokinetically (Pk)-Guided Dosing Versus Body Surface Area (BSA) Dosing of Paclitaxel (PTX) in Advanced Non-Small Cell Lung Cancer (NSCLC) NCT02058433

Olaparib in Combination with Paclitaxel in Patients with Advanced Gastric Cancer Who Have Progressed Following First-Line Therapy (GOLD): a Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial.

144O Comparison of Efficacy and Safety of Paclitaxel and Capecitabine Followed by Capecitabine As Maintenance Therapy Versus Cisplatin and Capecitabine Therapy for Advanced Gastric Cancer: a Multicentre, Randomised, Active-Controlled Phase III Study

Abstract 7632: Final survival outcomes and post-hoc tumor gene expression pathway analyses of complete responders from a phase Ib clinical trial of HSP90 inhibitor onalespib and paclitaxel in patients with advanced triple-negative breast cancer

Abstract IA012: Targeting AXL in platinum-resistant ovarian cancer: from the lab bench to Phase 3 trial

Abstract PS10-57: A Randomized, Multicenter, Open-Label Phase II/III Study of ARX788 Vs Lapatinib and Capecitabine in Patients with HER2-positive Locally Advanced or Metastatic Breast Cancer (ZMC-ARX788-211)

A multicenter randomized phase III study of albumin-bound paclitaxel combined with S-1 (AS) versus oxaliplatin combined with S-1 (SOX) for first-line treatment of advanced gastric cancer (GAPSO study).

HyperlynX: A Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and Radiotherapy in Patients with Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Abstract CT211: A phase 1 dose-escalation and dose-expansion study to evaluate the safety, pharmacokinetics, and anti- tumor activity of ARX517 in subjects with advanced solid tumors resistant or refractory to standard therapies (APEX-01 trial, NCT04662580)

AXLerate-OC/GOG-3059/ENGOT OV-66: Results of a phase 3, randomized, double-blind, placebo/paclitaxel-controlled study of batiraxcept (AVB-S6-500) in combination with paclitaxel in patients with platinum-resistant recurrent ovarian cancer.

863OAxitinib vs placebo in patients at high risk of recurrent renal cell carcinoma (RCC): ATLAS trial results

Paclitaxel Oral Solution Versus Paclitaxel Injection As Second-Line Therapy in Advanced Gastric Cancer: A Randomized, Open-Label, Non-Inferiority Phase 3 Trial.

Abstract LB023: A novel oral Paclitaxel delivery strategy and softgel capsule product for improving cancer therapeutics

Phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of adagloxad simolenin (OBI-822) and OBI-821 treatment in patients with early-stage triple-negative breast cancer (TNBC) at high risk for recurrence.

Phase 2 clinical trial of the proautophagic drug ABTL0812 combined with paclitaxel and carboplatin in first-line patients with advanced squamous non-small cell lung carcinoma.